Resistance to AC220 in FLT3-ITD+ AML is mediated by a secondary FLT3-ITD F691L mutation

被引：0
|
作者：
Albers, C. [1 ]
Leischner, H. [1 ,2 ]
Verbeek, M. [1 ]
Yu, C. [1 ]
von Bubnoff, N. [1 ]
Peschel, C. [1 ]
Duyster, J. [1 ]
机构：
[1] III Med Dept, Munich, Germany
[2] HELIOS Klinikum Berlin Buch, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：117 / 117
页数：1
相关论文
共 50 条
  • [1] The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib
    C Albers
    H Leischner
    M Verbeek
    C Yu
    A L Illert
    C Peschel
    N von Bubnoff
    J Duyster
    Leukemia, 2013, 27 : 1416 - 1418
  • [2] The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib
    Albers, C.
    Leischner, H.
    Verbeek, M.
    Yu, C.
    Illert, A. L.
    Peschel, C.
    von Bubnoff, N.
    Duyster, J.
    LEUKEMIA, 2013, 27 (06) : 1416 - 1418
  • [3] Overcoming AC220 resistance of FLT3-ITD by SAR302503
    M Kesarwani
    E Huber
    M Azam
    Blood Cancer Journal, 2013, 3 : e138 - e138
  • [4] Overcoming AC220 resistance of FLT3-ITD by SAR302503
    Kesarwani, M.
    Huber, E.
    Azam, M.
    BLOOD CANCER JOURNAL, 2013, 3 : e138 - e138
  • [5] An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/ F691L
    Wang, Xiuqi
    Defilippis, Rosa Anna
    Weldemichael, Tsigereda
    Gunaganti, Naresh
    Tran, Phuc
    Leung, Yuet-Kin
    Shah, Neil P.
    Li, Hong-yu
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 264
  • [6] DISRUPTING CDKN1A SECONDARY TO FLT3/ITD INHIBITION IS RESPONSIBLE FOR RESISTANCE TO FLT3/ITD INHIBITOR AC220 IN FLT3/ITD+ CELLS
    Fukuda, Seiji
    Abe, Mariko
    Hirade, Tomohiro
    Yamaguchi, Seiji
    EXPERIMENTAL HEMATOLOGY, 2015, 43 (09) : S63 - S63
  • [7] AC220, a Potent and Specific FLT3 Inhibitor, Enhances the Activity of Combined Cytarabine and Daunorubicin Chemotherapy in a FLT3-ITD Model of AML
    Belli, Barbara A.
    Dao, Alan
    Wierenga, Wendell
    Armstrong, Robert C.
    BLOOD, 2011, 118 (21) : 668 - 669
  • [8] Terminal Differentiation of FLT3/ITD AML Blasts In Patients Treated with the FLT3 Inhibitor AC220
    Levis, Mark J.
    Sexauer, Amy
    Rajkhowa, Trivikram
    Small, Donald
    Borowitz, Michael J.
    BLOOD, 2010, 116 (21) : 288 - 289
  • [9] HYPOXIA REGULATES FLT3-ITD EXPRESSION AND FUNCTION IN AML CELL-LINES HARBOURING A FLT3-ITD MUTATION
    Sironi, S.
    Wagner, M.
    Vasold, J.
    Drolle, H.
    Fiegl, M.
    ANNALS OF HEMATOLOGY, 2013, 92 : S12 - S13
  • [10] Combining Dasatinib and AC220 Reduces Stroma-Based pSTAT5Y694 in FLT3-ITD+ AML and Overcomes FLT3 TKI Resistance
    Patel, Ami B.
    Pomicter, Anthony D.
    Yan, Dongqing
    Eiring, Anna M.
    Franzini, Anca
    O'Hare, Thomas
    Deininger, Michael W.
    BLOOD, 2018, 132
12345